Gossamer Bio, Inc.
General ticker "GOSS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $419.0M (TTM average)
Gossamer Bio, Inc. does not follow the US Stock Market performance with the rate: -25.9%.
Estimated limits based on current volatility of 4.9%: low 0.16$, high 0.18$
Factors to consider:
- Total employees count: 145 (+7.4%) as of 2024
- Top business risk factors: Limited operating history, Need for additional capital, Clinical trial failure, Manufacturing risks, Regulatory and compliance
- Current price 90.9% below estimated low
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.89$, 5.30$]
- 2026-12-31 to 2027-12-31 estimated range: [1.48$, 4.20$]
Financial Metrics affecting the GOSS estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.65 <= 0.28
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Investing cash flow per share per price, % of 20.68 > -0.64
Short-term GOSS quotes
Long-term GOSS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $114.70MM | $48.47MM |
| Operating Expenses | $183.76MM | $174.62MM | $219.20MM |
| Operating Income | $-183.76MM | $-59.92MM | $-170.73MM |
| Non-Operating Income | $3.94MM | $4.28MM | $0.27MM |
| Interest Expense | $13.51MM | $11.52MM | $10.99MM |
| R&D Expense | $135.30MM | $138.49MM | $174.09MM |
| Income(Loss) | $-179.82MM | $-55.63MM | $-170.46MM |
| Taxes | $0.00MM | $0.89MM | $-0.09MM |
| Net Income(Loss)* | $-179.82MM | $-56.53MM | $-170.37MM |
| Stockholders Equity | $62.77MM | $29.49MM | $-122.76MM |
| Assets | $311.92MM | $315.29MM | $172.25MM |
| Operating Cash Flow | $-159.16MM | $-3.47MM | $-171.27MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.08MM |
| Investing Cash Flow | $-110.97MM | $29.02MM | $156.36MM |
| Financing Cash Flow | $190.15MM | $-11.49MM | $6.42MM |
| Earnings Per Share** | $-0.80 | $-0.25 | $-0.75 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.